Animal models in the drug discovery pipeline for Alzheimer's disease

This review paper summarizes and critically evaluates currently available animal models, and discusses their value to the Alzheimer drug discovery pipeline.

This review paper summarizes and critically evaluates currently available animal models, and discusses their value to the Alzheimer drug discovery pipeline.

7 - Role of Animal Models in Alzheimer's Disease Drug Development

Animal model systems play a fundamental role in the development and evaluation of novel treatments for Alzheimer's disease (AD).

Translational animal models for Alzheimer's disease: An Alzheimer's ...

The strongest translatable drug development association to date has been with drugs designed to lower amyloid/Aβ levels. Many reports and ...

Van Dam, D. and De Deyn, P.P. (2011) Animal Models in the Drug ...

Van Dam, D. and De Deyn, P.P. (2011) Animal Models in the Drug Discovery Pipeline for Alzheimer's Disease. British Journal of Pharmacology,164, 1285-1300.

Animal models in the drug discovery pipeline for Alzheimer's disease.

Animal models in the drug discovery pipeline for Alzheimer's disease. · Van Dam, Debby; De Deyn, Peter Paul · British Journal of Pharmacology, 2011, Vol 164, ...

Animal Models in Drug Discovery | Taconic Biosciences

Over the past century these and other species have been used to advance our knowledge of disease, to test new drugs, and to assure their safety ...

Animal Models of Neurodegenerative Disease: Recent Advances in ...

A major hurdle in the development of therapeutics is the issue of translatability from rodent models to humans. Many therapeutics show promising results in ...

Animal models of Alzheimer's disease: preclinical insights and ...

This article systematically reviews the animal models available for AD research, including transgenic, chemical- or drug-induced, and spontaneous animal models.

Drug pipeline in neurodegeneration based on transgenic mice ...

▻ One hundred and forty-six substances from 11 mouse models have been collected identified by data mining of the PubMed database from 2001 to 2011. ▻ Transgenic ...

Alzheimer's disease drug-development pipeline: few candidates ...

Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist.

Recent advances in Alzheimer's disease: mechanisms, clinical trials ...

... disease drug innovations from the research pipeline to patients ... Pathogenesis, Animal Models, and Drug Discovery of Alzheimer's Disease.

Animal Models of Dementia - SpringerLink

In Animal Models of Dementia, expert researchers provide contributions that stress the importance of extensively validated animal models in drug discovery and ...

Are some animal models more equal than others? A case study on ...

Our conclusion is that currently no animal models exist which are predictive for the efficacy of interventions for Alzheimer's disease.

Modeling Alzheimer's disease with non-transgenic rat models

The first transgenic mouse model of AD was developed 22 years ago. Based on the current condition of the AD drug pipeline, the limitations of ...

How does a researcher choose the best rodent model for their ...

available animal models and discusses their value to the. Alzheimer drug discovery pipeline. Models dealt with include spontaneous models in ...

Role of Animal Models in Alzheimer's Disease Drug Development

With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an ...

The need for better AD animal models - Frontiers

Drug development for Alzheimer's disease (AD) has proven to be particularly difficult. Only five symptomatic drugs have been approved for its treatment between ...

Full article: How does a researcher choose the best rodent model for ...

Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol. 2011;164:1285–1300.

Alzheimer's Disease: Novel Targets and Investigational Drugs for ...

Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD) comprise 70% of the AD drug development pipeline of agents currently in ...